Key Takeaways The S&P 500 added 0.5% on Wednesday, July 2, 2025, reaching a record-high close for the second time this week, as the U.S. announced a trade deal with Vietnam.Coinbase shares rose. The ...

With Terrana Biosciences, Moderna founder Flagship can apply its RNA knowledge to agricultural use cases like pest and disease resistance.

This article makes a valuable contribution to the field by uncovering a molecular mechanism for miRNA intracellular retention, mediated by the interaction of PCBP2, SYNCRIP, and specific miRNA motifs.

While biopharmaceutical technologies have made substantial strides in treating diseases, drug research and development ...

A University of California, Riverside-led team has made an advance in the basic understanding of Plasmodium falciparum, the ...

As part of the deal, AbbVie will acquire Capstan's targeted LNP platform technology and its lead candidate for B cell-mediated autoimmune diseases.

Terrana Biosciences will develop crop protection inputs using RNA technology, which was used by Flagship portfolio company Moderna to develop its covid-19 vaccine.

With a $50 million initial investment from Flagship, Terrana will use RNA from benign plant viruses as a chassis to carry ...

Terrana is aiming to have commercially available products in the next few years, pending regulatory approval, that can be applied as sprayables or seed treatments. And the company says its RNA-based ...

Ranjan Narula and Shakti Priyan Nair of RNA, Technology and IP Attorneys examine how Indian law and recent court rulings have ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...